The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older and those 12 to 64 years old with at least one underlying condition that could put them at risk of severe infection,

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283),

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing Covid shot does not currently face.